• Hiromitsu Kitayama, Yasushi Tsuji, Junko Sugiyama, Ayako Doi, Tomohiro Kondo, and Michiaki Hirayama.
• Department of Medical Oncology, Tonan Hospital, Kita 1 Jo Nishi 6 Chome, Chuo-ku, Sapporo, Hokkaido, 060-0001, Japan. m02032hk@jichi.ac.jp.
• Int. J. Clin. Oncol. 2015 Dec 1; 20 (6): 1051-6.

BackgroundAlthough palonosetron (PALO) and NK1 receptor antagonist both reduce chemotherapy-induced nausea and vomiting, no comparison trial in moderately emetogenic chemotherapy (MEC) had been reported. The purpose of this study was to find out which drug combinations are preferable for patients receiving MEC.MethodsChemotherapy-naive patients receiving MEC were randomized to two groups; group A first received PALO therapy [PALO plus 1-day dexamethasone (DEX)], and group B first received fosaprepitant (FAPR) therapy [FAPR, granisetron (GRAN), and DEX]. Patients were re-allocated to the other therapy, respectively, for the second cycle of chemotherapy. We administered intravenous PALO (0.75 mg) and DEX (9.9 mg) to the PALO therapy group, and FAPR (150 mg), DEX (4.95 mg), and GRAN (3 mg) to the FAPR therapy group, on Day 1. Complete response (CR) was the primary endpoint; complete control (CC), total control (CT), and the therapy chosen by the patients for their third and following cycles of antiemetic therapy were the secondary endpoints. We evaluated CR, CC, and TC in the acute phase, in the delayed phase, and over the whole period.ResultsA total of 35 patients and 70 cycles of therapy was evaluable for analysis. No significant difference was found at all evaluation points. Overall CR rates for PALO and FAPR therapy were 74 vs 69 % (P = 0.567), CC rates 66 vs 69 % (P = 0.521), and TC rates 46 vs 60 % (P = 0.235), respectively. Patients also showed no clear preference for their third and following cycles of chemotherapy, choosing both regimens almost equally often (PALO 10 vs FAPR 13).ConclusionsPALO and 1-day DEX is almost equivalent to FAPR, GRAN, and DEX for MEC.

36 keywords...

hide…